Introduction
Although urologists increasingly employ more extended prostate biopsy schemes for initial biopsies, the rate of repeat biopsies continues to rise [1] . Advances in technology and improved understanding of prostate cancer have not eliminated the questions surrounding the issue of repeat biopsies. What are the most reliable indications for repeat biopsy? How many biopsy cores should be obtained for optimal diagnostic yield to reduce the incidence of false-negative biopsies? What areas of the prostate should be biopsied to give the best diagnostic results? What is the best time interval between repeat biopsies? To how many repeat biopsy sessions should a patient be subjected?
Indications for Repeat Biopsy
Indications for repeat biopsies include sustained or worsening elevation of total serum prostate-specifi c antigen (PSA) or other PSA parameters. The histology from the initial biopsy may also encourage repeat biopsy if high-grade prostatic intraepithelial neoplasia (HGPIN) or atypical small acinar proliferation (ASAP) is identifi ed. Risk factors such as family history of prostate cancer and African American race have not been evaluated as potential indications for repeat biopsy but often impact urologists' attitudes toward encouraging patients to undergo repeat biopsy. Patient anxiety about the possibility of prostate cancer is another common but difficult indication to quantitate for repeat biopsy.
Repeat biopsy for PSA An elevated or rising PSA level is the most common indication for repeat prostate biopsies. A PSA level over 4 ng/mL is generally accepted as an indication for initial biopsy, whereas some urologists will biopsy for a PSA over 2.5 ng/mL or adjust the acceptable upper limit of normal PSA for the patient's age. For repeat prostate biopsies after an initial set has been free of cancer, a PSA greater than 10 ng/mL is agreed upon as a clear indication for the need for repeat biopsies, although repeat biopsies are not felt to be strongly indicated for a PSA less than 4 ng/mL [2] [3] [4] . PSA levels between 4 and 10 ng/mL present a signifi cant range in which the indications for repeat biopsy are less obvious. Other PSA parameters can facilitate the decision to perform repeat biopsies. These include the percent free PSA, PSA velocity (PSAV), PSA density (PSAD), and PSA density of the transition zone (PSAD-TZ).
Percent free PSA
The majority of serum PSA is attached to either alpha1-antichymotrypsin or alpha2-macroglobulin. The remainder of the serum PSA that is not bound to these molecules is referred to as the "free" PSA and is decreased in the serum relative to the proportion of bound PSA in patients with cancer. The percentage of the total PSA (the bound and free PSA combined) that consists of the free PSA portion is termed the percent free PSA. The percent free PSA has good utility in predicting cancer presence, specifi cally in men with PSA levels of 4 to 10 ng/mL. Catalona et al.
[5] demonstrated that percent free PSA cutoff of less than 25% corresponded with the highest cancer detection rate and the least number of unnecessary biopsies. Djavan et al.
[2] recommend a percent free PSA of less than 30% as one of the most accurate predictors of a positive repeat biopsy result. Morgan et al. [6] demonstrated that a percent free PSA less than 10% was a strong predictor for prostate cancer on repeat biopsy even after two negative prior biopsies with a sensitivity of 91% and a specifi city of 86%.
PSA density PSAD is calculated by dividing the PSA value by the prostatic volume. This calculation targets the problem of PSA elevation caused by benign prostatic hyperplasia and, when elevated, has been shown to correlate with the existence of cancer. Keetch et al. [7] evaluated density to assist in determining the need for a repeat biopsy. Using a value of 0.15 ng/mL/cm 3 , they reported missing 35% of the cancers. However, in conjunction with a PSAV greater than 0.75 ng/mL/y, they had a detection rate of 46% on repeat biopsy versus only 13% when both values were below the suggested cutoff. Djavan et al.
[2] evaluated PSAD but showed increased utility when it was related to PSAD-TZ. Using a value of 0.13 ng/mL/cm 3 for PSAD, the authors reported a sensitivity of 74% and a specifi city of 44%; for a value of 0.26 ng/mL/cm 3 for PSA-TZ, they reported a sensitivity of 78% and a specifi city of 52%. Calculating the PSAD-TZ has the potential for a high rate of error due to the need for high-resolution ultrasound equipment and an experienced sonographer because the margins of the transition zone are not as clearly demarcated as those of the entire prostate [3] .
PSA velocity PSAV is determined by taking the difference between two PSA values and dividing by the time interval between the two levels in years. PSAV has found more utility as a tool to predict recurrence in patients already diagnosed with prostate cancer but also has been employed as a predictor of biopsy outcome. In a comparison to other PSA parameters, Borboroglu et al. [8] found that a PSAV of greater than 0.75 ng/mL/y was the only statistically signifi cant risk factor for prostate cancer detection on biopsy. However, the European Randomized Study of Screening for Prostate Cancer failed to show clinical utility for either PSAV or PSA doubling time (PSADT) [9] . PSADT is another measure of PSA change over time but has similarly demonstrated more utility in the prediction of prostate cancer aggressiveness than as an indication for repeat biopsy.
Many investigators have now come to the conclusion that no single PSA parameter is adequate to indicate the need for repeat biopsies. Keetch et al. [7] determined that using only PSAV greater than 0.75 ng/mL/y would miss a large number of cancers and recommended combining the PSAV other parameters. Djavan et al. [2] recommend the combination of a percent free PSA of less than 30% and/or a PSAD-TZ ≥ 0.26 ng/mL/cm 3 as the most accurate predictor of a positive repeat biopsy result in patients with PSA levels between 4 and 10 ng/mL. Busby and Evans [3] recommend a combination of total PSA, percent free PSA, PSAD, and PSAV based on analysis of the published data on each of these parameters. Their recommended PSAbased indications for repeat biopsy include any patient with a PSA in the 4 to 10 ng/mL range and a percent free PSA less than 25%. For patients with a PSA between 4 to 10 ng/ mL and percent free PSA greater than 25%, repeat biopsies are recommended if they have a PSAD greater than 0.15 ng/mL/cm 3 and a PSAV greater than 0.75 ng/mL/y, a PSAV greater than 1 ng/mL/y, or a PSAD-TZ greater than 0.26 ng/mL/y. Both Djavan et al. [2] and Busby and Evans [3] recommend repeat biopsy in any patient with a PSA greater than 10 ng/mL regardless of the other parameters. Busby and Evans [3] qualify this recommendation by stating that patients with PSA greater than 10 ng/mL with infl ammation noted histologically should have a trial of antibiotics and repeat PSA before considering repeat biopsy.
Repeat biopsy for HGPIN
HGPIN is characterized by prostatic glands in which the epithelial cells exhibit the nuclear enlargement and prominent nucleoli characteristic of prostatic adenocarcinoma, yet with a preserved basal cell layer. Although the presence of a basal cell layer excludes the diagnosis of invasive cancer, HGPIN is thought to be a precursor to invasive adenocarcinoma [10] . After evaluating pathology trends on 62,537 initial prostate needle core biopsies submitted by offi ce-based urologists (processed at a single pathology laboratory), isolated HGPIN was diagnosed in 4.1% of the biopsies [11] . In a referral academic practice employing extended fi eld biopsies for initial prostate tissue sampling, 22% of cases exhibited isolated HGPIN [12] .
After sextant biopsy results showed HGPIN, 80% of patients demonstrated cancer on repeat biopsy [13] . With extended biopsy schemes showing HGPIN, the rate of cancer detection on repeat biopsies was only 23% [14] . This decreased cancer detection rate after extended biopsy schemes is probably due to the better sampling and increased likelihood of identifying coexisting cancer and HGPIN on the initial extended biopsy procedure.
Low-grade prostatic intraepithelial neoplasia (LGPIN) does not carry the same risk of concomitant cancer. Zlotta and Schulman [15] found that LGPIN was associated with subsequent cancer on repeat biopsies in 10.7% of patients with a PSA between 4 and 10 ng/mL and in none of the cases when PSA was ≤ 4 ng/mL. LGPIN is not considered an indication for repeat biopsy unless other factors, such as an elevated PSA, increase the suspicion of prostate cancer. In fact, the notation of the presence of LGPIN has been discouraged from being mentioned in pathology reports.
Although most experts recommend repeat biopsy for patients with HGPIN on initial biopsy, with the recent more widespread use of extended biopsy schemes, immediate repeat biopsy may not be necessary because the cancer detection rate is similar to initial biopsy in this setting [3,16•] . If HGPIN is again identifi ed on repeat biopsy but cancer is not diagnosed, follow-up PSA and examination in 6 months is recommended.
Repeat biopsy for ASAP
ASAP is a focus of small glands that have the cytologic appearance of malignancy; however, the presence or absence of the basal cell layer is equivocal [17] . Rather than a premalignant lesion, this fi nding is felt to often represent invasive cancer that is simply diffi cult for the
